Musk threatens Liberal’s fake “energy crisis”

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Robert Meyer Biography and Net Worth

Director of Chimerix

Dr. Meyer has served as one of our directors since March 2018. He currently serves as Principal, Drug and Biological Products at Greenleaf Health, an FDA-focused strategic advising company. He is also an Associate Professor of Public Health Sciences at the University of Virginia, where he was formerly the Director of the Virginia Center for Translational and Regulatory Sciences from 2013-2017. He has also served on the board of Translate Bio, Lexington MA since 2019. Dr. Meyer previously was on the board of Correvio Pharma (nee Cardiome) and was a Trustee of the US Pharmacopeia for the 2015-2020 cycle. Prior to joining the faculty at UVA, Dr. Meyer was Vice President and Head, Global Regulatory Strategy, Policy and Safety at Merck Research Laboratories (MRL), joining Merck in October 2007. Prior to Merck, Dr. Meyer worked for the U.S. Food and Drug Administration (FDA) from 1994-2007. In his last 5 years at the FDA, Dr. Meyer was the Director for the Office of Drug Evaluation II (ODEII) within Center for Drug Evaluation and Research (CDER), with responsibilities for pulmonary and allergy, metabolic and endocrine, and analgesics, anesthetics and rheumatologic drug products. Dr. Meyer holds a B.A. from Lehigh University and an M.D. from the University of Connecticut School of Medicine.

What is Robert J. Meyer's net worth?: The estimated net worth of Robert J. Meyer is at least $98,771.50 as of May 8th, 2023. Mr. Meyer owns 35,150 shares of Chimerix stock worth more than $98,772 as of December 18th. This net worth evaluation does not reflect any other assets that Mr. Meyer may own. Learn More about Robert J. Meyer's net worth.
How do I contact Robert J. Meyer?: The corporate mailing address for Mr. Meyer and other Chimerix executives is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. Chimerix can also be reached via phone at (919) 806-1074 and via email at [email protected]. Learn More on Robert J. Meyer's contact information.
Has Robert J. Meyer been buying or selling shares of Chimerix?: Robert J. Meyer has not been actively trading shares of Chimerix in the last ninety days. Most recently, on Monday, May 8th, Robert J. Meyer bought 8,750 shares of Chimerix stock. The stock was acquired at an average cost of $1.14 per share, with a total value of $9,975.00. Following the completion of the transaction, the director now directly owns 35,150 shares of the company's stock, valued at $40,071. Learn More on Robert J. Meyer's trading history.
Who are Chimerix's active insiders?: Chimerix's insider roster includes David Jakeman (Insider), Robert Meyer (Director), and Fred Middleton (Director). Learn More on Chimerix's active insiders.
Are insiders buying or selling shares of Chimerix?: In the last twelve months, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 7,629 shares worth more than $7,664.31. The most recent insider tranaction occured on August, 8th when CEO Michael T Andriole sold 1,285 shares worth more than $1,066.55. Insiders at Chimerix own 13.1% of the company. Learn More about insider trades at Chimerix.
Information on this page was last updated on 8/8/2024.

Robert J. Meyer Insider Trading History at Chimerix

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/8/2023	Buy	8,750	$1.14	$9,975.00	35,150
5/19/2022	Buy	11,400	$2.06	$23,484.00	26,400
3/1/2021	Buy	1,500	$9.80	$14,700.00	15,000
8/19/2020	Buy	3,500	$2.92	$10,220.00
11/6/2019	Buy	10,000	$1.58	$15,800.00	10,000

Robert J. Meyer Buying and Selling Activity at Chimerix

Chimerix Company Overview

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Today's Range

Now: $2.81

$2.75

$3.02

50 Day Range

MA: $1.11

$0.83

$2.98

2 Week Range

Now: $2.81

$0.75

$3.39

Volume

2,118,960 shs

Average Volume

1,257,564 shs

Market Capitalization

$252.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02